Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 High-frequency aflibercept injections in persistent neovascular age-related macular degeneration.

× No keyword cloud information.

9 in total

1. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes.

Authors: Sylvie Julien; Antje Biesemeier; Tatjana Taubitz; Ulrich Schraermeyer
Journal: Br J Ophthalmol Date: 2014-01-23 Impact factor: 4.638

2. Long-term Outcomes of Aflibercept Treatment for Neovascular Age-related Macular Degeneration in a Clinical Setting.

Authors: Dan Călugăru; Mihai Călugăru
Journal: Am J Ophthalmol Date: 2016-12-23 Impact factor: 5.258

3. Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration.

Authors: Dan Călugăru; Mihai Călugăru
Journal: Am J Ophthalmol Date: 2016-11-11 Impact factor: 5.258

4. Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy.

Authors: D Călugăru; M Călugăru
Journal: Eye (Lond) Date: 2016-10-07 Impact factor: 3.775

5. Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration.

Authors: Dan Călugăru; Mihai Călugăru
Journal: Am J Ophthalmol Date: 2016-12-05 Impact factor: 5.258

6. High-frequency aflibercept injections in persistent neovascular age-related macular degeneration.

Authors: Ilkay Kilic Muftuoglu; Frank F Tsai; Raouf Gaber; Mostafa Alam; Amit Meshi; William R Freeman
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2016-11-23 Impact factor: 3.117

7. Choroidal Thickness Changes After Intravitreal Antivascular Endothelial Growth Factor Therapy for Age-Related Macular Degeneration: Ranibizumab Versus Aflibercept.

Authors: Magda Gharbiya; Filippo Cruciani; Cesare Mariotti; Francesca Grandinetti; Marco Marenco; Vittorio Cacace
Journal: J Ocul Pharmacol Ther Date: 2015-06-03 Impact factor: 2.671

8. Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid.

Authors: Glenn J Jaffe; Peter K Kaiser; Desmond Thompson; Andrea Gibson; Namrata Saroj; Robert Vitti; Alyson J Berliner; Jeffrey S Heier
Journal: Ophthalmology Date: 2016-06-28 Impact factor: 12.079

9. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.

Authors: Nicholas Papadopoulos; Joel Martin; Qin Ruan; Ashique Rafique; Michael P Rosconi; Ergang Shi; Erica A Pyles; George D Yancopoulos; Neil Stahl; Stanley J Wiegand
Journal: Angiogenesis Date: 2012-06 Impact factor: 9.596

9 in total

3 in total

1. Comment on "Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration".

Authors: Dan Călugăru; Mihai Călugăru
Journal: Int J Ophthalmol Date: 2018-11-18 Impact factor: 1.779

2. The fate of eyes with wet AMD beyond 4 years of anti-VEGF therapy.

Authors: Dan Călugăru; Mihai Călugăru
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2018-05-07 Impact factor: 3.117

3. Comment on "Intravitreal conbercept injection for neovascular age-related macular degeneration".

Authors: Dan Călugăru; Mihai Călugăru
Journal: Int J Ophthalmol Date: 2020-02-18 Impact factor: 1.779

3 in total